XOMA Royalty (XOMA) Intangibles (2022 - 2026)
XOMA Royalty's (XOMA) quarterly Intangibles came in at $43.9 million in Q1 2026, up 72.93% year-on-year from $25.4 million in Q1 2025, and down 1.99% quarter-over-quarter from $44.8 million in Q4 2025.
XOMA Royalty (XOMA) Intangibles (2022 - 2026) Analysis & Trends
XOMA Royalty has disclosed Intangibles across 5 years of filings, most recently posting $43.9 million for Q1 2026.
- Intangibles for Q1 2026 came in at $43.9 million, up 72.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.9 million (up 72.93% YoY), and the FY2025 annual result was $44.8 million, up 72.74% from the prior year.
- Intangibles came in at $43.9 million for Q1 2026 at XOMA Royalty, down from $44.8 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $45.4 million in Q2 2025 to a low of $14.5 million in Q3 2023.
- The 5-year median for Intangibles is $25.4 million (2025), against an average of $27.7 million.
- Across the five-year window, Intangibles changed 0.0% in 2023 and jumped 72.93% in 2026, its largest moves.
- XOMA Royalty's Intangibles stood at $15.2 million in 2022, then changed by 0.0% to $15.2 million in 2023, then jumped by 69.93% to $25.9 million in 2024, then soared by 72.74% to $44.8 million in 2025, then dropped by 1.99% to $43.9 million in 2026.
- The last three Intangibles figures came in at $43.9 million (Q1 2026), $44.8 million (Q4 2025), and $44.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 4.41 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 418.50 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 7.73 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 43.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.86 Mn |
| Dec 31, 2025 | 44.76 Mn |
| Sep 30, 2025 | 44.56 Mn |
| Jun 30, 2025 | 45.43 Mn |
| Mar 31, 2025 | 25.37 Mn |
| Dec 31, 2024 | 25.91 Mn |
| Dec 31, 2023 | 15.25 Mn |
| Sep 30, 2023 | 14.48 Mn |
| Jun 30, 2023 | 14.70 Mn |
| Mar 31, 2023 | 14.93 Mn |
| Dec 31, 2022 | 15.25 Mn |